Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.

Rodbard HW, Bellary S, Hramiak I, Seino Y, Silver R, Damgaard LH, Nayak G, Zacho J, Aroda VR.

Endocr Pract. 2019 Jun;25(6):589-597. doi: 10.4158/EP-2018-0444. Epub 2019 Mar 13.

PMID:
30865526
2.

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.

Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, Alexander CM, Battelino T, Ampudia-Blasco FJ, Bode BW, Cariou B, Close KL, Dandona P, Dutta S, Ferrannini E, Fourlanos S, Grunberger G, Heller SR, Henry RR, Kurian MJ, Kushner JA, Oron T, Parkin CG, Pieber TR, Rodbard HW, Schatz D, Skyler JS, Tamborlane WV, Yokote K, Phillip M.

Diabetes Care. 2019 Jun;42(6):1147-1154. doi: 10.2337/dc18-2316. Epub 2019 Feb 6. Review.

PMID:
30728224
3.

A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes.

Tibaldi J, Hadley-Brown M, Liebl A, Haldrup S, Sandberg V, Wolden ML, Rodbard HW.

Diabetes Obes Metab. 2018 Dec 15. doi: 10.1111/dom.13616. [Epub ahead of print]

4.

Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis.

Bowering K, Rodbard HW, Russell-Jones D, Bode B, Harris S, Piletic M, Heller S, Woo V, Babu V, Dethlefsen C, Mathieu C.

Diabetes Ther. 2019 Feb;10(1):177-188. doi: 10.1007/s13300-018-0553-7. Epub 2018 Dec 13.

5.

The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs.

Rodbard HW.

Diabetes Technol Ther. 2018 Jun;20(S2):S233-S241. doi: 10.1089/dia.2018.0103. Epub 2018 Jun 5.

PMID:
29870275
6.

Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.

Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, Araki E, Chu PL, Wijayasinghe N, Norwood P.

J Clin Endocrinol Metab. 2018 Jun 1;103(6):2291-2301. doi: 10.1210/jc.2018-00070.

7.

Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.

Billings LK, Doshi A, Gouet D, Oviedo A, Rodbard HW, Tentolouris N, Grøn R, Halladin N, Jodar E.

Diabetes Care. 2018 May;41(5):1009-1016. doi: 10.2337/dc17-1114. Epub 2018 Feb 26.

PMID:
29483185
9.

Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).

Rodbard HW, Tripathy D, Vidrio Velázquez M, Demissie M, Tamer SC, Piletič M.

Diabetes Obes Metab. 2017 Oct;19(10):1389-1396. doi: 10.1111/dom.12955. Epub 2017 Jul 6.

10.

The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes.

Rodbard HW, Peters AL, Slee A, Cao A, Traina SB, Alba M.

Diabetes Care. 2017 Feb;40(2):171-180. doi: 10.2337/dc16-1353. Epub 2016 Nov 29.

PMID:
27899497
11.
12.

Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.

Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2016 Dec;39(12):2304-2310. Epub 2016 Oct 14.

PMID:
27742728
13.

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.

Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW; TECOS Study Group.

Diabetes Obes Metab. 2017 Jan;19(1):78-86. doi: 10.1111/dom.12786. Epub 2016 Oct 6.

PMID:
27607571
14.

Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.

Rodbard HW, Bode BW, Harris SB, Rose L, Lehmann L, Jarlov H, Thurman J; Dual Action of Liraglutide and insulin degludec (DUAL) IV trial investigators.

Diabet Med. 2017 Feb;34(2):189-196. doi: 10.1111/dme.13256. Epub 2016 Oct 7.

15.

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.

Rodbard HW, Seufert J, Aggarwal N, Cao A, Fung A, Pfeifer M, Alba M.

Diabetes Obes Metab. 2016 Aug;18(8):812-9. doi: 10.1111/dom.12684. Epub 2016 Jun 7.

16.

Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.

Rodbard HW, Cariou B, Pieber TR, Endahl LA, Zacho J, Cooper JG.

Diabetes Obes Metab. 2016 Mar;18(3):274-80. doi: 10.1111/dom.12609. Epub 2016 Jan 11.

17.

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.

Buse JB, Rodbard HW, Trescoli Serrano C, Luo J, Ivanyi T, Bue-Valleskey J, Hartman ML, Carey MA, Chang AM; IMAGINE 5 Investigators.

Diabetes Care. 2016 Jan;39(1):92-100. doi: 10.2337/dc15-1531. Epub 2015 Nov 17.

PMID:
26577417
18.

IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal Test.

Holst JJ, Buse JB, Rodbard HW, Linjawi S, Woo VC, Boesgaard TW, Kvist K, Gough SC.

J Diabetes Sci Technol. 2015 Oct 6;10(2):389-97. doi: 10.1177/1932296815610124.

19.

Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.

Rodbard HW, Buse JB, Woo V, Vilsbøll T, Langbakke IH, Kvist K, Gough SC.

Diabetes Obes Metab. 2016 Jan;18(1):40-8. doi: 10.1111/dom.12574. Epub 2015 Nov 5.

20.

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.

Ahmann A, Rodbard HW, Rosenstock J, Lahtela JT, de Loredo L, Tornøe K, Boopalan A, Nauck MA; NN2211-3917 Study Group.

Diabetes Obes Metab. 2015 Nov;17(11):1056-64. doi: 10.1111/dom.12539. Epub 2015 Sep 10.

21.

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial.

Gough SC, Bode BW, Woo VC, Rodbard HW, Linjawi S, Zacho M, Reiter PD, Buse JB.

Diabetes Obes Metab. 2015 Oct;17(10):965-73. doi: 10.1111/dom.12498. Epub 2015 Jul 1.

22.
23.

Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators.

Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1.

PMID:
25190523
24.

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).

Buse JB, Vilsbøll T, Thurman J, Blevins TC, Langbakke IH, Bøttcher SG, Rodbard HW; NN9068-3912 (DUAL-II) Trial Investigators.

Diabetes Care. 2014 Nov;37(11):2926-33. doi: 10.2337/dc14-0785. Epub 2014 Aug 11.

PMID:
25114296
25.

Treatment intensification with stepwise addition of prandial insulin aspart boluses compared with full basal-bolus therapy (FullSTEP Study): a randomised, treat-to-target clinical trial.

Rodbard HW, Visco VE, Andersen H, Hiort LC, Shu DH.

Lancet Diabetes Endocrinol. 2014 Jan;2(1):30-7. doi: 10.1016/S2213-8587(13)70090-1. Epub 2013 Sep 25. Erratum in: Lancet Diabetes Endocrinol. 2014 Jan;2(1):e3.

PMID:
24622667
26.

Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare).

Bode BW, Chaykin LB, Sussman AM, Warren ML, Niemeyer M, Rabøl R, Rodbard HW.

Endocr Pract. 2014 Aug;20(8):785-91. doi: 10.4158/EP13411.OR.

PMID:
24518180
27.

Health status and hypoglycaemia with insulin degludec versus insulin glargine: a 2-year trial in insulin-naïve patients with type 2 diabetes.

Rodbard HW, Cariou B, Zinman B, Handelsman Y, Wolden ML, Rana A, Mathieu C.

Diabetes Obes Metab. 2014 Sep;16(9):869-72. doi: 10.1111/dom.12271. Epub 2014 Feb 27.

28.

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON).

Mathieu C, Rodbard HW, Cariou B, Handelsman Y, Philis-Tsimikas A, Ocampo Francisco AM, Rana A, Zinman B; BEGIN: VICTOZA ADD-ON (NN1250-3948) study group.

Diabetes Obes Metab. 2014 Jul;16(7):636-44. doi: 10.1111/dom.12262. Epub 2014 Feb 11.

PMID:
24443830
29.

Increased priority for regimens involving incretin-based and insulin therapy.

Rodbard HW.

J Fam Pract. 2013 Dec;62(12 Suppl CME):S5-11. Review.

PMID:
24340348
30.

Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.

Rodbard HW, Gough S, Lane W, Korsholm L, Bretler DM, Handelsman Y.

Endocr Pract. 2014 Apr;20(4):285-92. doi: 10.4158/EP13287.OR.

PMID:
24246344
31.

Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.

Rodbard HW, Cariou B, Zinman B, Handelsman Y, Philis-Tsimikas A, Skjøth TV, Rana A, Mathieu C; BEGIN Once Long trial investigators.

Diabet Med. 2013 Nov;30(11):1298-304. doi: 10.1111/dme.12303. Epub 2013 Sep 30.

32.

One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.

Rosenstock J, Rodbard HW, Bain SC, D'Alessio D, Seufert J, Thomsen AB, Svendsen CB, DeVries JH; Liraglutide-Detemir Study Group.

J Diabetes Complications. 2013 Sep-Oct;27(5):492-500. doi: 10.1016/j.jdiacomp.2013.04.008. Epub 2013 Jun 6.

33.

Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.

Hirsch IB, Buse JB, Leahy J, McGill JB, Peters A, Rodbard HW, Rubin RR, Skyler JS, Verderese CA, Riddle MC.

Diabetes Obes Metab. 2014 Mar;16(3):206-14. doi: 10.1111/dom.12136. Epub 2013 Jun 20. Review.

PMID:
23711193
34.

Physicians' prescribing patterns for patients with diabetes are changing for the better.

Rodbard HW, Jellinger PS.

Am J Med. 2012 Nov;125(11):e11-2. doi: 10.1016/j.amjmed.2012.04.035. No abstract available.

PMID:
23098867
35.

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long).

Zinman B, Philis-Tsimikas A, Cariou B, Handelsman Y, Rodbard HW, Johansen T, Endahl L, Mathieu C; NN1250-3579 (BEGIN Once Long) Trial Investigators.

Diabetes Care. 2012 Dec;35(12):2464-71. doi: 10.2337/dc12-1205. Epub 2012 Oct 5.

37.

A critique of the 2012 ADA/EASD position statement.

Rodbard HW, Jellinger PS.

Diabetologia. 2012 Oct;55(10):2850-2852. doi: 10.1007/s00125-012-2646-6. Epub 2012 Jul 18. No abstract available.

PMID:
22801905
38.

Oral pharmacologic treatment of type 2 diabetes mellitus.

Rodbard HW, Jellinger PS.

Ann Intern Med. 2012 Jul 3;157(1):75-6; author reply 76-7. doi: 10.7326/0003-4819-157-1-201207030-00017. No abstract available.

PMID:
22751768
39.

Rate and risk predictors for development of self-reported type-2 diabetes mellitus over a 5-year period: the SHIELD study.

Rodbard HW, Bays HE, Gavin JR 3rd, Green AJ, Bazata DD, Lewis SJ, Fox KM, Reed ML, Grandy S.

Int J Clin Pract. 2012 Jul;66(7):684-91. doi: 10.1111/j.1742-1241.2012.02952.x.

PMID:
22698420
40.

Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets.

DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J; Liraglutide-Detemir Study Group.

Diabetes Care. 2012 Jul;35(7):1446-54. doi: 10.2337/dc11-1928. Epub 2012 May 14.

41.

American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis.

Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis.

Endocr Pract. 2012 Mar-Apr;18 Suppl 1:1-78. No abstract available.

PMID:
22522068
42.

American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary.

Jellinger PS, Smith DA, Mehta AE, Ganda O, Handelsman Y, Rodbard HW, Shepherd MD, Seibel JA; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis.

Endocr Pract. 2012 Mar-Apr;18(2):269-93. No abstract available.

PMID:
22507559
43.

Use of an automated decision support tool optimizes clinicians' ability to interpret and appropriately respond to structured self-monitoring of blood glucose data.

Rodbard HW, Schnell O, Unger J, Rees C, Amstutz L, Parkin CG, Jelsovsky Z, Wegmann N, Axel-Schweitzer M, Wagner RS.

Diabetes Care. 2012 Apr;35(4):693-8. doi: 10.2337/dc11-1351. Epub 2012 Feb 16.

44.
45.

Adding noninsulin antidiabetic drugs to metformin therapy for type 2 diabetes.

Rodbard HW, Jellinger PS.

JAMA. 2010 Jul 28;304(4):405-6; author reply 406-7. doi: 10.1001/jama.2010.1021. No abstract available.

PMID:
20664035
46.

American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Practice Guidelines--2010 update.

Mechanick JI, Camacho PM, Cobin RH, Garber AJ, Garber JR, Gharib H, Petak SM, Rodbard HW, Trence DL; American Association of Clinical Endocrinologists.

Endocr Pract. 2010 Mar-Apr;16(2):270-83.

PMID:
20350905
47.

Impact of type 2 diabetes mellitus on prescription medication burden and out-of-pocket healthcare expenses.

Rodbard HW, Green AJ, Fox KM, Grandy S; SHIELD Study Group.

Diabetes Res Clin Pract. 2010 Mar;87(3):360-5. doi: 10.1016/j.diabres.2009.11.021. Epub 2010 Jan 4.

PMID:
20047768
48.

Trends in Method of Diagnosis of Type 2 Diabetes Mellitus: Results from SHIELD.

Rodbard HW, Green AJ, Fox KM, Grandy S.

Int J Endocrinol. 2009;2009:796206. doi: 10.1155/2009/796206.

49.

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS.

Endocr Pract. 2009 Sep-Oct;15(6):540-59. Erratum in: Endocr Pract. 2009 Nov-Dec;15(7):768-70.

PMID:
19858063
50.

Impact of obesity on work productivity and role disability in individuals with and at risk for diabetes mellitus.

Rodbard HW, Fox KM, Grandy S; Shield Study Group.

Am J Health Promot. 2009 May-Jun;23(5):353-60. doi: 10.4278/ajhp.081010-QUAN-243.

PMID:
19445439

Supplemental Content

Loading ...
Support Center